Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Communicable Disease Center. Poliomyelitis Surveillance Report No. 248. Atlanta, GA: 1962.
Eddy BE, Borman GS, Berkley WH, Young RD. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med 1961;107:191–197.
Diamandopoulos GT. Induction of lymphocyte leukemia, lymphosarcoma, reticulum cell sarcoma and osteogenetic sarcoma in the Syrian golden hamster by ontogenetic DNA simian virus 40. J Natl Cancer Inst 1973;50:1347–1365.
Kirschstein RL, Gerber P. Ependymomas produced after intracerebral inoculation of SV40 into newborn hamsters. Nature 1962;195:298–300.
Rabson AS, O’Conor GT, Kirschstein RL, Branigan WJ. Papillary ependymomas produced in Rattus (mastomys) natalensis inoculated with vacuolating virus (SV40). J Natl Cancer Inst 1962;29:765–787.
Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993;142:1524–1533.
Eddy BE, Borman GS, Grubbs G, Young RD. Identification of the oncogenic substance in rhesus monkey kidney cell cultures as simian virus 40. Virology 1962;17:65–75.
Koprowski H, et al. Transformation of cultures of human tissue infected with simian virus 40. J Cell Comp Physiol 1962;59:281–292.
Gerber P, Hottle GA, Grubbs G. Inactivation of vacuolating virus (SV40) by formaldehyde. Proc Soc Exp Biol Med 1961;108:205–209.
Shah KV, Willard S, Myers RE, et al. Experimental infections of rhesus with simian virus 40 (SV40). Proc Soc Exp Biol Med 1968;130:196–203.
Melnick JL, Stinbaugh S. Excretion of vacuolating SV40 virus (papovirus group) after ingestion as a contaminant of oral poliovaccine. Proc Soc Exp Biol Med 1962;109:965–968.
Morris JA, Johnson KM, Aulisio CG, Chanock RM, Knight V. Clinical and serologic responses in volunteers given vacuolating virus (SV40) by respiratory route. Proc Soc Exp Biol Med 1961;108:56–59.
Pan American Health Organization and World Health Organization. Field evidence in safety, topic II (B). In: Second International Conference on Live Poliovirus Vaccines. Washington, DC: 1960:113–227.
Fraumeni JF, Ederer F, Miller RW. An evaluation of the carcinogenecity of simian virus 40 in man. JAMA 1963;185:713–718.
Fraumeni JF, Stark CR, Gold E, Lepow MC. Simian virus 40 in polio vaccine: follow-up of newborn recipients. Science 1970;167:59–60.
Mortimer EA Jr, Lepow MC, Gold E, Robbins FC, Burton GJ, Fraumeni JF Jr. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981;305:1517–1518.
Carroll-Pankhurst C, Engels EA, Strickler HD, Goedert JJ, Wagner J, Mortimer EA. Thirty-five year mortality following receipt of SV40-contaminated polio vaccine during neonatal period. Br J Cancer 2001;85:1295–1297.
Martini F, Iaccheri L, et al. SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from health individuals. Cancer Res 1996;56(20):4820–4825.
Shah K, Nathanson N. Human exposure to SV40: reviews and comments. Am J Epidemiol 1976;103:1–12.
Hammond EC. Cancer mortality in relation to SV40 in polio vaccine. Presented at the American Cancer Society Sciences Writers’ Seminar, 1966.
Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 1973;2:229–234.
Innis MD. Oncogenesis and poliomyelitis vaccine. Nature 1968;219:972–973.
Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact in cancer incidence rates 1960–63. Dev Biol Stand 1998;4:227–233.
Geiseler E. SV40 and human brain tumors. Prog Med Virol 1990;37:211–222.
Strickler HD, Rosenberg PS, Devesa GG, Hertel J, Fraumeni JF, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates. JAMA 1998;279:292–295.
Fisher SG, Weber L, Carbone M. Cancer risk associated with simian virus 40 contaminated polio vaccine. Anticancer Res 1999;19:2173–2180.
Strickler HD, Goedart JJ, Devesa SS, Lancy J, Fraumeni JF, Rosenberg PS. Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 2003;95:38–45.
Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211–218.
Stratton K, Almario DA, McCormick MC, eds. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC. Institute of Medicine, National Academies Press, 2002.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Fisher, S.G. (2005). From Monkey to Man: The Epidemiologic Evidence of an Association Between Simian Virus 40 and Malignancy. In: Pass, H.I., Vogelzang, N.J., Carbone, M. (eds) Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/0-387-28274-2_18
Download citation
DOI: https://doi.org/10.1007/0-387-28274-2_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-22949-2
Online ISBN: 978-0-387-28274-9
eBook Packages: MedicineMedicine (R0)